DOCSLIB.ORG

How to Prepare for Expert Testimony on the Safety of Vaccination Stanley A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
How to Prepare for Expert Testimony on the Safety of Vaccination Stanley A How to Prepare for Expert Testimony on the Safety of Vaccination Stanley A. Plotkin, MD The Centers for Disease Control and Prevention has recently announced that vaccine coverage in American children has begun to decline as more parents seek medical, religious, and so-called philosophical exemptions. The proportion of unvaccinated American children has now reached 1.3%.1 This was a depressing announcement but not surprising in view of the increase in antivaccinationism, or as it is euphemistically called, “vaccine hesitancy.” One of the reasons for the decline in vaccination became clear to me in January 2018, when I was asked to do a pro bono deposition in a case The Wistar Institute, University of Pennsylvania, Children’s Hospital of in which a father who wanted his daughter vaccinated before entering Philadelphia, and Vaxconsult, Philadelphia, Pennsylvania kindergarten was suing his divorced wife, who opposes vaccination. I DOI: https://doi.org/10.1542/peds.2018-3578 accepted because I viewed it as a public service, and I thought I merely had to testify about the benefits of vaccination and its overall safety. Accepted for publication Nov 29, 2018 Address correspondence to Stanley A. Plotkin, MD, Department However, when I arrived at the conference room where the deposition was of Pediatrics, University of Pennsylvania, Vaxconsult, 4650 to be conducted, I found 2 lawyers representing the mother. I later learned Wismer Rd, Doylestown, PA 18902. E-mail: stanley.plotkin@ that 1 of the lawyers was a partner at a New York City law firm that vaxconsult.com specializes in vaccine injury and antivaccination suits. The firm represents PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098- those opposed to mandatory vaccination. As an example, it opposed 4275). a regulation in New York that would allow a child with a sexually Copyright © 2019 by the American Academy of Pediatrics transmitted disease to be vaccinated against human papillomavirus FINANCIAL DISCLOSURE: Dr Plotkin is a paid consultant to 2,3 without parental permission. Sanofi Pasteur, GlaxoSmithKline, Merck, Pfizer, Inovio That lawyer grilled me for 10 consecutive hours on subjects ranging from Pharmaceuticals, Variations Bio, Takeda Pharmaceutical Company, Dynavax Technologies, Serum Institute of India, putative vaccine reactions, the potential dangers of adjuvants in vaccines CureVac, Valneva SE, Hookipa Pharma, and NTxBio. Vaxconsult (including aluminum), the causes of autism, possible contaminants in gives advice to vaccine developers. vaccines, and other antivaccination tropes. I was also confronted with FUNDING: No external funding. vaccine package inserts that describe hundreds of supposed reactions and POTENTIAL CONFLICT OF INTEREST: Dr Plotkin is a paid asked details about the oral polio vaccination in what was then called the consultant to Sanofi Pasteur, GlaxoSmithKline, Merck, Pfizer, Belgian Congo that I was involved in during the 1950s. Table 1 includes Inovio Pharmaceuticals, Variations Bio, Takeda Pharmaceutical a sampling of the subjects about which I was questioned. The opposing Company, Dynavax Technologies, Serum Institute of India, attorney was clearly skilled and knowledgeable about vaccination CureVac, Valneva SE, Hookipa Pharma, and NTxBio. Vaxconsult practices. He came armed with numerous articles on the subject of vaccine gives advice to vaccine developers. safety. As someone who has been working in vaccinology since the 1950s and who is the chief editor of the textbook Vaccines, I think I know To cite: Plotkin SA. How to Prepare for Expert Testimony Pediatrics something about the subject, but I did not have articles at my fingertips on the Safety of Vaccination. 2019;143(4): e20183578 and had to depend on my memory. Downloaded from www.aappublications.org/news by guest on September 28, 2021 PEDIATRICS Volume 143, number 4, April 2019:e20183578 PEDIATRICS PERSPECTIVES In his questioning, the lawyer TABLE 1 Some of the Subjects on Which I Was Questioned by an Antivaccination Lawyer During constantly referred to articles of a Deposition doubtful scientific quality, and I was Subject reminded that an appreciation of the Money I have received from vaccine companies differences between valid studies and Have I done any consulting for the government despite having consulted for the industry? those of poor quality is understood by Is the pertussis vaccine effective? scientists, but judges and lawyers What royalties have I received for vaccine invention? Do vaccines have nonspecific effects, such as increased mortality after DTP (shown by Dr Peter Aaby)? may be misled by some of the Some package inserts seem to say subjects in vaccine trials were only managed for 4–5d. thousands of articles published each According to the package insert, Salk IPV reactions were only managed for 2 d. year, many of which are published for How was MMR safety documented? Where are safety data? Was there an unvaccinated group managed profit and lack scientific integrity. at the same time? This makes it difficult for lawyers and A Gardasil safety study used the Alum adjuvant as a control, not a placebo, so how can you exclude reactions? Of the control group, 2%–3% had reactions said to be autoimmune; so did Gardasil. judges to distinguish truth from The National Academy of Medicine published a book that says many reactions may have been caused by misrepresentation. vaccines. What proof is there that DTaP doesn’t cause autism? Therefore, I am concerned about Is there a study comparing vaccinated and unvaccinated children for health later in life? future expert witnesses in cases Can Alum travel to the brain and cause autism? involving vaccine safety. It is IL-6 is induced by vaccination and can cause autism. important that they have the latest Package inserts mention encephalopathy as a possible reaction to influenza and pertussis vaccines. data from scientifically reliable Some vaccines were produced in monkey cells; therefore, monkey DNA and protein are in the vaccine. Human diploid cell proteins are in vaccines made in MRC-5. studies. With the help of Dr Paul Offit Can adjuvants increase responses to nonvaccine antigens in vaccines? and Heather Bodenstab, we have What about my work with the oral polio vaccine in the Belgian Congo in the 1950s? Did I vaccinate created a library at the Children’s anyone without permission? Hospital of Philadelphia that contains What’s the evidence that receiving multiple vaccines at the same time is safe? references on vaccine safety from DTaP, diphtheria-tetanus-acellular pertussis; DTP, diphtheria-tetanus toxoids-pertussis vaccine; IL-6, interleukin-6; IPV, reliable medical literature. The library inactivated polio vaccine; MMR, measles-mumps-rubella vaccine; MRC-5, Medical Research Council cell strain 5. isaccessiblethroughthehospital’sWeb site (vaccine.chop.edu/safety- the package insert about the efficacy Society should provide training to references). This resource is designed of the vaccine. I am campaigning with vaccine experts on how to give to help expert witnesses but will also the Food and Drug Administration testimony. If possible, it would be serve pediatricians who wish to inform and vaccine manufacturers to add the useful to identify and train a panel of themselves about vaccine safety. missing information to the package experts who would agree to present Another aspect of the questioning inserts. It would help if organizations the science in vaccine-related legal was related to package inserts for such as the American Academy of contests. Moreover, they will need vaccines. On this topic, I had to agree Pediatrics actively supported those training to deal with the legal concept with the opposing lawyer that they changes in the package circulars. of reasonable doubt, by which a poor- are incomplete documents written quality study is used to question the Although in this case the judge ruled primarily (although imperfectly) to overall data in favor of safety. If this is in favor of vaccination, I am protect the manufacturers from legal not done, lawyers such as the one I convinced that the antivaccination attack. In addition to pertinent safety faced will have a significant negative movement is much better organized information, the package inserts list impact on vaccination, raising costs than the pediatric community, and if numerous putative reactions to each and diminishing coverage. We must nothing is done to correct this vaccine, as reported by physicians to not allow our child patients to be imbalance, vaccine coverage will the Vaccine Adverse Events Reporting unprotected as a result of the decrease further. It is crucial that System from empirical experience. antivaccination movement’s specious future expert witnesses be better The inserts say nothing about the and unfounded objections or prepared with scientific information overall safety record, which may be otherwise unsound positions enabling extensive rebuttals. Just as based on millions of subjects. The transmitted through the legal system important, they should be prepared description in the inserts of crucial like an infectious disease. by defense lawyers (which I was not) trials seem to imply that safety was about how to handle questions that observed only over a few days are not grounded in accepted science. postinoculation, and they ignore the REFERENCES reality of longer follow-up in safety In addition, organizations such as the 1. Hill HA, Elam-Evans LD, Yankey D, trials plus data accumulated through American Academy of Pediatrics and Singleton JA, Kang Y. Vaccination years of use. More should be said in the Pediatric Infectious Diseases coverage among children aged Downloaded from www.aappublications.org/news by guest on September 28, 2021 2 PLOTKIN 19-35 months - United States, 2017. Available at: https://www.health.ny.gov/ Raptor. March 9, 2017. Available at: MMWR Morb Mortal Wkly Rep. 2018; prevention/immunization/laws_regs. https://www.skepticalraptor.com/ 67(40):1123–1128 htm. Accessed December 5, 2018 skepticalraptorblog.php/hpv-vaccine- 2. New York State Department of Health. 3. Rubenstein Rice D. HPV vaccine consent consent-case-new-york-review/. Immunization laws and regulations.
Load more

Recommended publications
  • Stanley A. Plotkin, MD
    55936.qxp 3/10/09 4:27 PM Page 4 Stanley A. Plotkin, MD Recipient of the 2009 Maxwell Finland Award for Scientific Achievement hysician, scientist, scholar—Stanley Plotkin Dr. Plotkin was born in New York City. His father was a has successfully juggled all three roles during commercial telegrapher. His mother, who occasionally his decades of service. filled in as an accountant, mostly stayed home with Stanley PFrom his first job following graduation from and his younger sister, Brenda. At age 15, Stanley, a student medical school as an intern at Cleveland Met- at the Bronx High School of Science, discovered what he ropolitan General Hospital to his present role as consultant wanted to do with his life. After reading the novel Arrow - to the vaccine manufacturer sanofi pasteur, Dr. Plotkin has smith by Sinclair Lewis and the nonfictional work Microbe explored the world of infectious diseases and Hunters by Paul de Kruif—two books about sci- has been actively involved in developing some entists battling diseases—Stanley set his sights of the most potent vaccines against those dis- on becoming a physician and a research scien- eases. tist. “Dr. Plotkin has been a tireless advocate for Dr. Plotkin graduated from New York Uni- the protection of humans, and children in par- versity in 1952 and obtained a medical degree ticular, from preventable infectious diseases. at Downstate Medical Center in Brooklyn. He His lifetime of work on vaccines has led to pro- was a resident in pediatrics at the Children’s found reductions in both morbidity and mortality not only Hospital of Philadelphia and at the Hospital for Sick Chil- in the United States, but throughout the world,” says Vi- dren in London.
    [Show full text]
  • Vaccine Hesitancy
    WHY CHILDREN WORKSHOP ON IMMUNIZATIONS ARE NOT VACCINATED? VACCINE HESITANCY José Esparza MD, PhD - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA - Robert Koch Fellow, Robert Koch Institute, Berlin, Germany - Senior Advisor, Global Virus Network, Baltimore, MD, USA. Formerly: - Bill & Melinda Gates Foundation, Seattle, WA, USA - World Health Organization, Geneva, Switzerland The value of vaccination “The impact of vaccination on the health of the world’s people is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth” Stanley Plotkin (2013) VACCINES VAILABLE TO PROTECT AGAINST MORE DISEASES (US) BASIC VACCINES RECOMMENDED BY WHO For all: BCG, hepatitis B, polio, DTP, Hib, Pneumococcal (conjugated), rotavirus, measles, rubella, HPV. For certain regions: Japanese encephalitis, yellow fever, tick-borne encephalitis. For some high-risk populations: typhoid, cholera, meningococcal, hepatitis A, rabies. For certain immunization programs: mumps, influenza Vaccines save millions of lives annually, worldwide WHAT THE WORLD HAS ACHIEVED: 40 YEARS OF INCREASING REACH OF BASIC VACCINES “Bill Gates Chart” 17 M GAVI 5.6 M 4.2 M Today (ca 2015): <5% of children in GAVI countries fully immunised with the 11 WHO- recommended vaccines Seth Berkley (GAVI) The goal: 50% of children in GAVI countries fully immunised by 2020 Seth Berkley (GAVI) The current world immunization efforts are achieving: • Equity between high and low-income countries • Bringing the power of vaccines to even the world’s poorest countries • Reducing morbidity and mortality in developing countries • Eliminating and eradicating disease WHY CHILDREN ARE NOT VACCINATED? •Vaccines are not available •Deficient health care systems •Poverty •Vaccine hesitancy (reticencia a la vacunacion) VACCINE HESITANCE: WHO DEFINITION “Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination services.
    [Show full text]
  • White Paper on Studying the Safety of the Childhood Immunization Schedule for the Vaccine Safety Datalink
    White Paper on Studying the Safety of the Childhood Immunization Schedule For the Vaccine Safety Datalink National Center for Emerging and Zoonotic Infectious Diseases Immunization Safety Office CS258953 White Paper on the Safety of the Childhood Immunization Schedule Vaccine Safety Datalink Centers for Disease Control and Prevention | 1600 Clifton Road | Atlanta GA 30329 Notice: The project that is the subject of this report was approved and funded by the Immunization Safety Office, Centers for Disease Control and Prevention. The contributors responsible for the content of the White Paper were funded by Task Order contract 200-2012-53582/0004 awarded as a prime contract to Kaiser Foundation Hospitals. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Additional copies of this report are available from Jason Glanz, PhD, [email protected] Contributors to the White Paper on the Study of the Safety of the Childhood Immunization Schedule Study Team Authors Jason M. Glanz, PhD Lead Investigator, Kaiser Permanente Colorado, Denver, CO; Assistant Professor of Epidemiology, University of Colorado School of Public Health, Aurora, CO. Sophia R. Newcomer, MPH Co-Investigator, Kaiser Permanente Colorado, Denver, CO. Mike L. Jackson, PhD, MPH Co-Investigator, Group Health Cooperative, Seattle, WA. Saad B. Omer, MBBS, MPH, PhD Co-Investigator and Associate Professor of Global Health, Epidemiology, and Pediatrics at Emory University, Schools of Public Health and Medicine, Atlanta, GA. Robert A. Bednarczyk, PhD Co-Investigator and Assistant Professor of Global Health, Emory University School of Public Health, Atlanta, GA.
    [Show full text]
  • An Epidemic and Social Taboos
    BOOK REVIEW An epidemic and social taboos the mothers of infants with cataracts whose discussion about the rubella they had in early pregnancy was overheard by Gregg, but she doesn’t Dangerous Pregnancies give him sufficient credit for making the mental leap to convert gossip to scientific fact. Reagan also exaggerates the early opposition to Gregg’s Leslie J. Reagan hypothesis about rubella being teratogenic, which was simply scientific University of California Press, 2010 skepticism pending confirmation by other workers. 392 pp., hardcover, $29.95 However, Reagan well describes the fierce opposition in some quarters ISBN: 9780520259034 to medical abortions given to women who were diagnosed with rubella during pregnancy. She recounts several legal battles that arose from Reviewed by Stanley A Plotkin abortions done or abortions refused and how they resulted in relaxation of abortion rules before the Roe vs. Wade decision of the US Supreme Court in 1973 at last struck down all barriers. I had forgotten that, in California in 1968, several physicians were convicted of malpractice in a suit brought by the state attorney general. Fortunately, that decision was reversed. In another instance, a physician from Minnesota who Perhaps the most accurate view of current events is through the ‘ret- purposely precipitated a 1970 criminal case by performing a medically rospectoscope,’ for those who live through them often do not perceive indicated abortion was mercilessly prosecuted and lost her license. their long-term importance. At least that thought came to mind while Reagan gives the rubella epidemic a major role in the liberalization of I was reading Dangerous Pregnancies by Leslie Reagan.
    [Show full text]
  • Dissemination of Vaccine Misinformation on Twitter and Its Countermeasures
    Dissertation Dissemination of Vaccine Misinformation on Twitter and Its Countermeasures Christine Chen This document was submitted as a dissertation in March 2021 in partial fulfillment of the requirements of the doctoral degree in public policy analysis at the Pardee RAND Graduate School. The faculty committee that supervised and approved the dissertation consisted of Luke Matthews (Chair), Sarah Nowak and Jeremy Miles. The external reader was Jennifer Golbeck. This dissertation was generously supported by the Anne and James Rothenberg Dissertation Award. PARDEE RAND GRADUATE SCHOOL For more information on this publication, visit http://www.rand.org/pubs/rgs_dissertations/RGSDA1332-1.html Published 2021 by the RAND Corporation, Santa Monica, Calif. is a registered trademarK Limited Print and Electronic Distribution Rights This document and trademarK(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited. Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Permission is reQuired from RAND to reproduce, or reuse in another form, any of its research documents for commercial use. For information on reprint and linking permissions, please visit www.rand.org/pubs/permissions.html. The RAND Corporation is a research organization that develops solutions to public policy challenges to help maKe communities throughout the world safer and more secure, healthier and more prosperous. RAND is nonprofit, nonpartisan, and committed to the public interest. RAND’s publications do not necessarily reflect the opinions of its research clients and sponsors. Support RAND MaKe a tax-deductible charitable contribution at www.rand.org/giving/contribute www.rand.org Abstract Outbreaks of vaccine preventable diseases have continued to affect many parts of the United States.
    [Show full text]
  • Valneva Appoints Renowned Vaccinologists Stanley Plotkin and Anna Durbin to Its Scientific Advisory Board
    VALNEVA SE Campus Bio-Ouest | 6, Rue Alain Bombard 44800 Saint-Herblain, France Valneva Appoints Renowned Vaccinologists Stanley Plotkin and Anna Durbin to its Scientific Advisory Board Saint-Herblain (France), December 9, 2019 – Valneva SE (“Valneva” or “the Company”) today announced the appointment of two leading vaccine experts to its Scientific Advisory Board (SAB). Dr. Stanley A. Plotkin, MD and Dr. Anna Durbin, MD, have joined Valneva’s SAB. Dr. Stanley Plotkin serves as a consultant to the vaccine industry and is an emeritus professor at both the Wistar Institute and University of Pennsylvania. He developed the rubella vaccine, which is now used worldwide, and has played a pivotal role in both the development and application of various other vaccines including polio, rabies, varicella, rotavirus and cytomegalovirus. He is the author of more than 800 research papers and has edited several books including the textbook Vaccines. Dr. Plotkin has served as the senior assistant surgeon with the Epidemic Intelligence Service, U.S. Public Health Service, director of the division of infectious diseases at Children’s Hospital of Philadelphia, associate Chairman of the department of pediatrics at the University of Pennsylvania and Medical Director at Sanofi Pasteur for seven years. Dr. Anna Durbin is a professor of international health at Johns Hopkins University’s Bloomberg School of Public Health with a joint appointment in the School of Medicine. She is trained in Internal Medicine and Infectious Diseases. Dr. Durbin joined the Center for Immunization Research in 1999 as a Principal Investigator conducting clinical trials for live attenuated flavivirus vaccines. She has expertise in the evaluation of a variety of vaccines, including dengue, West Nile and malaria.
    [Show full text]
  • Summary of CEPI Scientific Advisory Committee (SAC) Meeting Teleconference, 13.05.2020
    Summary of CEPI Scientific Advisory Committee (SAC) meeting Teleconference, 13.05.2020 Attendees Voting SAC members CEPI Secretariat • Alan D. Barrett • Richard Hatchett • Alash´le Abimiku • Frederik Kristensen • Christian Bréchot • Melanie Saville • Christian Happi • Nick Jackson • Connie Schmaljohn • Raimonda Viburiene • Daniel Brasseur • Stig Tollefsen • Delese Mimi Darko • Ingrid Kromann • Helen Rees (Chair) • Inger Damon • Bill Dowling • James Robinson (Vice chair) • Jakob Cramer • John Edmunds • Debra Yeskey • Michel De Wilde • Svein Rune Andersen • Myron Levin • Gabrielle Breugelmans • Penny Heaton • Paul Kristiansen • Peter Smith • Amy C. Shurtleff • Phil Krause • Ralf Clemens • Other CEPI staff as observers • Stanley Plotkin • Tom Kariuki Invitees • Yves Levy • Anna-Maria Henao Restrepo, WHO • Simon Funnell, PHE Non-voting members • Charlie Weller Wellcome Trust • Ali Alloueche • César Muñoz-Fontela, BNITM • Jean Lang • Alina Ximena, WHO • Johan Van Hoof • Pierre Gsell, WHO • Josie Golding • Vaseeharan Sathiyamoorthy, WHO Meeting minutes Welcome and brief introduction of today’s item Helen Rees and Richard Hatchett, CEO of CEPI, opened the SAC teleconference by welcoming everyone and thanking the Team for the efforts to prepare for this meeting. #1 The ACT Accelerator 1 Richard Hatchett briefly introduced the Access to COVID-19 Tools (ACT) Accelerator, a landmark collaboration to accelerate the development, production and equitable distribution of vaccines, diagnostics and therapeutics for COVID-19. A draft version of the governance structure of the Vaccine pillar - COVAX, was introduced, one of the three pillars under the ACT Accelerator. CEPI and Gavi have been named as co-convenors and representatives from both organisations and the World Health Organization (WHO) are working on further structure of COVAX.
    [Show full text]
  • INOVIO Announces Publication of Phase 1 Data from Its COVID-19 DNA Vaccine Candidate, INO-4800 in the Lancet's Eclinicalmedicine
    NEWS RELEASE INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine 12/24/2020 Peer-reviewed Phase 1 data shows INO-4800 to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses INO-4800 demonstrates favorable safety and tolerability, with no serious adverse events reported Oers best-in-class thermostability, including a ve-year projected shelf life at normal refrigeration temperature and no frozen transport or storage requirements PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the publication of peer-reviewed Phase 1 clinical data from the rst cohort of 40 participants for its COVID-19 DNA vaccine candidate, INO-4800, in EClinicalMedicine, an open access clinical journal published by The Lancet. The paper, titled "Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial," found that INO-4800 was immunogenic in all vaccinated subjects, eectively generating an immune response of humoral (including neutralizing antibodies) and/or cellular responses (both CD4 and CD8 T cells). Additionally, Phase 1 clinical data found INO-4800 to have a favorable safety and tolerability prole with no serious adverse events reported; only six Grade 1 adverse events (AEs) were observed, primarily minor injection site reactions. Notably, these only occurred on the day of the rst or second dosing, and the AEs did not increase in frequency with the second administration.
    [Show full text]
  • Why an HIV Vaccine Is Scientifically Possible Scientifically Possible by Margaret Johnston, Ph.D
    A Newsletter on International AIDS Vaccine Research Vol.1 No. 1 Summer 1996 INSIDE THIS ISSUE Why an HIV Vaccine is Why an HIV Vaccine is Scientifically Possible Scientifically Possible by Margaret Johnston, Ph.D. IAVI's scientific director makes the case for why an ore than 12 years after HIV was identified The scientific rationale for supporting this claim HIV vaccine is feasible. Mas the causative agent for AIDS, enormous includes the following: -1- challenges remain in the effort to develop a safe 1.Vaccines are effective against and effective HIV vaccine. At this point, not a A View from Uganda many viral diseases. Dr. Edward Mbidde, one of single candidate vaccine has progressed beyond Vaccines work by stimulating specific immuno- Uganda’s leading researchers, phase II trials. Some even suggest that the goal of discusses AIDS vaccines logical memory against an infectious agent such developments. developing an HIV vaccine is unattainable. as a virus. Successful vaccination enables an -3- Yet, a close look at recent scientific advances — individual to mount a rapid and potent immune both in understanding the pathogenesis of AIDS Progress On AIDS Vaccines response when exposed to a particular virus.This and in testing experimental HIV/SIV vaccines — A closer look at a number increased immune response holds the virus in of HIV vaccines currently in suggests that the development of an AIDS vaccine check and prevents all signs of disease. A development and their is feasible. In fact, many researchers now believe future prospects. successful HIV vaccine will either prevent HIV that, with the proper investment of global -4- infection or prevent disease by considerably resources and leadership, a vaccine for HIV is limiting HIV replication.
    [Show full text]
  • José Esparza MD, Phd - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
    Vaccination: lost opportunities José Esparza MD, PhD - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. - Formerly at the World Health Organization (Geneva, Switzerland) and the Bill & Melinda Gates Foundation (Seattle, WA, USA). Outline • The public health value of vaccination • Different types of vaccine hesitancy • Some historical examples of vaccine introduction and impact • The case of dengue vaccines • Conclusions Ten Great Public Health Achievements of the 20th Century (in the US) 1. Vaccines 2. Motor vehicle safety 3. Workplace safety 4. Control of infectious diseases 5. Decline in deaths from hearth disease and stroke 6. Safer and healthier foods 7. Healthier mothers and babies 8. Family planning 9. Fluoridation of drinking water 10. Tobacco as a health hazard www.cdc.gov/about/history/tengpha.htm The value of vaccination “The impact of vaccination on the health of the world’s people is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth” Stanley Plotkin (2013) Vaccine-preventable diseases, by year of vaccine development or licensure. United States,1798-1998. Vaccine Introduction Vaccine Introduction Smallpox 1798 Rubella 1969 Rabies 1885 Antrax 1970 Typhoid 1896 Meningitis 1975 Cholera 1896 Pneumonia 1977 Plague 1897 Adenovirus 1980 Diphtheria 1923 Hepatitis B 1981 Pertussis 1926 H. Influenza B 1985 Tetanus 1927 Japanese encephalitis 1992 Tuberculosis 1927 Hepatitis A 1995
    [Show full text]
  • History of Vaccination
    SPECIAL FEATURE: PERSPECTIVE PERSPECTIVE SPECIAL FEATURE: History of vaccination Stanley Plotkin1 Department of Pediatrics, University of Pennsylvania, Philadelphia, PA 19104 Edited by Rino Rappuoli, Novartis Vaccines, Siena, Italy, and approved February 5, 2014 (received for review January 13, 2014) Vaccines have a history that started late in the 18th century. From the late 19th century, vaccines could be developed in the laboratory. However, in the 20th century, it became possible to develop vaccines based on immunologic markers. In the 21st century, molecular biology permits vaccine development that was not possible before. killed vaccines | proteins | live vaccine | genetic engineering One of the brightest chapters in the history of in humans (7). This idea played a role in the varicella vaccines were all made possible science is the impact of vaccines on human development of bacillus Calmette–Guérin through selection of clones by cell-culture longevity and health. Over 300 y have elapsed but is even more obvious in the selection of passage in vitro (17–21). In essence, passage since the first vaccine was discovered. In rhesus and bovine rotavirus strains to aid in cell culture leads to adaptation to growth a short article, it is not possible to do justice the creation of human rotavirus vaccines as in that medium, and the mutants best capa- to a subject that encompasses immunology, mentioned below under Reassortment. bleofgrowthhaveoftenlostormodifiedthe molecular biology, and public health, but sev- It was Pasteur and his colleagues who most genes that allow them to infect and spread eral more extensive sources are available clearly formulated the idea of attenuation and within a human host.
    [Show full text]
  • Plotkin SHORT CV
    SHORT CV Dr. Stanley A. Plotkin is Emeritus Professor of the University of Pennsylvania, and Adjunct Professor of the Johns Hopkins University. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute and at the same time, Director of Infectious Diseases and Senior Physician at the Children’s Hospital of Philadelphia. In 1991, Dr. Plotkin left the University to join the vaccine manufacturer, Pasteur-Mérieux-Connaught, where for seven years he was Medical and Scientific Director, based at Marnes-la-Coquette, outside Paris. The same company is now named Sanofi Pasteur. He is now consultant to vaccine manufacturers, biotechnology companies and non-profit research organizations as principal of Vaxconsult, LLC. Dr. Plotkin attended New York University, where he received a B.A. degree, and then the State University of New York Medical School in Brooklyn, where he received an M.D. degree in 1956. His subsequent career included internship at Cleveland Metropolitan General Hospital, residency in pediatrics at the Children’s Hospital of Philadelphia and the Hospital for Sick Children in London and three years in the Epidemic Intelligence Service of the Centers for Disease Control of the US Public Health Service. He has been chairman of the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics, liaison member of the Advisory Committee on Immunization Practices and Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health. Dr. Plotkin received the Bruce Medal in Preventive Medicine of the American College of Physicians, the Distinguished Physician Award of the Pediatric Infectious Diseases Society, the Clinical Virology Award of the Pan American Society for Clinical Virology, the Richard Day Master Teacher in Pediatrics Award of the Alumni Association of New York Downstate Medical College, and the Marshall Award of the European Society for Pediatric Infectious Diseases.
    [Show full text]